Prostate Cancer Foundation
OrganisationROR
Trials
Collaborator, Phase 2, Recruiting, 58 people, 27 Sept 2024
Collaborator, Phase 1, Active, not recruiting, 3 people, 12 Mar 2024
Collaborator, Phase 2, Recruiting, 50 people, 28 Sept 2023
Collaborator, Phase 2, Completed, 23 people, 2 Jan 2017
Collaborator, Phase 2, Terminated, 2 people, 7 Dec 2016
Collaborator, Phase 2, Active, not recruiting, 45 people, 21 Nov 2013
Awards made
PCF Young Investigator Award, Assessing the Impact of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Advanced Prostate Cancer Risk and Outcomes, PCF-129633, 2025, 1 Jan 2025
PCF Young Investigator Award, Assessing the Impact of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Advanced Prostate Cancer Risk and Outcomes, PCF-129633, 2025, 1 Jan 2025
PCF Young Investigator Award, Validation and Clinical Qualification of Biomarkers Associated with PC Inflammation That Have Multi-Purpose Clinical Utility, PCF-116820, 2024, 1 Jan 2024
PCF Young Investigator Award, Validation and Clinical Qualification of Biomarkers Associated with PC Inflammation That Have Multi-Purpose Clinical Utility, PCF-116820, 2024, 1 Jan 2024
PCF Young Investigator Award, Investigating the Potential of Repurposing Anti-Diabetic/Obesity Drugs for the Treatment of Obesity-Driven Aggressive Prostate Cancer, PCF-116806, 2024, 1 Jan 2024
PCF Young Investigator Award, Investigating the Potential of Repurposing Anti-Diabetic/Obesity Drugs for the Treatment of Obesity-Driven Aggressive Prostate Cancer, PCF-116806, 2024, 1 Jan 2024
PCF Young Investigator Award, ProsGATE: Geriatric Assessment and Technology Evaluation in Prostate Cancer, PCF-116824, 2024, 1 Jan 2024
PCF Young Investigator Award, ProsGATE: Geriatric Assessment and Technology Evaluation in Prostate Cancer, PCF-116824, 2024, 1 Jan 2024
PCF Challenge Award, Germline Influence on Prostate Cancer Metastasis and Response to Androgen Deprivation Therapy, PCF-118908, 2023, 1 Jan 2023
University of Maryland, College Park
PCF Challenge Award, Germline Influence on Prostate Cancer Metastasis and Response to Androgen Deprivation Therapy, PCF-118908, 2023, 1 Jan 2023
PCF Challenge Award, Germline Influence on Prostate Cancer Metastasis and Response to Androgen Deprivation Therapy, PCF-118908, 2023, 1 Jan 2023
Massachusetts General Hospital
PCF Challenge Award, Germline Influence on Prostate Cancer Metastasis and Response to Androgen Deprivation Therapy, PCF-118908, 2023, 1 Jan 2023
PCF Challenge Award, Germline Influence on Prostate Cancer Metastasis and Response to Androgen Deprivation Therapy, PCF-118908, 2023, 1 Jan 2023
PCF Challenge Award, Germline Influence on Prostate Cancer Metastasis and Response to Androgen Deprivation Therapy, PCF-118908, 2023, 1 Jan 2023
University of California, San Diego
PCF Challenge Award, Germline Influence on Prostate Cancer Metastasis and Response to Androgen Deprivation Therapy, PCF-118908, 2023, 1 Jan 2023
University of California, San Francisco
PCF Challenge Award, Germline Influence on Prostate Cancer Metastasis and Response to Androgen Deprivation Therapy, PCF-118908, 2023, 1 Jan 2023
University of California Los Angeles
PCF Challenge Award, Germline Influence on Prostate Cancer Metastasis and Response to Androgen Deprivation Therapy, PCF-118908, 2023, Lead, 1 Jan 2023
PCF Young Investigator Award, MMUVE Prostate Cancer: Multi-Omic Evaluation of Micro-Ultrasound VisiblE Prostate Cancer, PCF-116511, 2023, 1 Jan 2023
University of California Los Angeles
PCF Young Investigator Award, MMUVE Prostate Cancer: Multi-Omic Evaluation of Micro-Ultrasound VisiblE Prostate Cancer, PCF-116511, 2023, 1 Jan 2023
PCF Challenge Award, Darostep: Evaluating Step Counts as a Biomarker and its Relationship on Treatment Outcomes in Vulnerable Patients with Metastatic Hormone-Sensitive Prostate Cancer on Darolutamide and Androgen Deprivation Therapy, PCF-113580, 2023, 1 Jan 2023
Sources: openalex.org
Funded papers
Mammography utilization and male breast cancer in BRCA1/2 carriers
18VALO08, 22CHAL02, 23 Sept 2026
22YOUN32, 31 Aug 2026
Sources: api.crossref.org